PET/Computed Tomography and Precision Medicine: Musculoskeletal Sarcoma

Area of Science:

• Oncology
• Nuclear Medicine
• Radiology

Background:

• Accurate diagnosis, staging, and treatment are vital for optimal outcomes in skeletal and soft tissue sarcomas.
• High-grade sarcomas require precise staging to guide treatment decisions.

Purpose of the Study:

• To highlight the role of 18F-FDG PET/CT in the staging and treatment assessment of sarcomas.
• To emphasize 18F-FDG PET/CT as a surrogate marker for histopathologic grade and a guide for biopsy.
• To evaluate the utility of 18F-FDG PET/CT in assessing response to therapy and guiding treatment modifications.

Main Methods:

• Utilizing 18F-FDG PET/CT for staging high-grade sarcomas.
• Employing pretherapy and posttherapy 18F-FDG PET/CT metabolic parameters.
• Assessing 18F-FDG PET/CT for evaluating molecular targeted therapies.

Main Results:

• 18F-FDG PET/CT serves as an indicator of histopathologic grade, directing biopsies to the most aggressive tumor regions.
• Pretherapy and posttherapy metabolic parameters from 18F-FDG PET/CT reliably predict survival in sarcoma patients.
• 18F-FDG PET/CT is effective in posttreatment response assessment, allowing for timely modification of treatment plans for nonresponders.

Conclusions:

• 18F-FDG PET/CT is essential for accurate sarcoma staging and treatment response evaluation.
• The technique's ability to detect early metabolic changes makes it valuable for assessing targeted therapies.
• 18F-FDG PET/CT facilitates personalized treatment strategies by identifying nonresponders early.